Kindeva Invests in Low-GWP Propellant Manufacturing Line

• Kindeva Drug Delivery has invested in a second manufacturing line for low-GWP propellant pMDI products at its Loughborough, U.K., facility.

• The new line, operational in 2026, will handle HFA-152a and HFO-1234ze propellants, significantly lower in GWP than the industry standard.

• This investment aligns with the recent adoption of F-gas legislation in the EU and increased customer demand for sustainable pMDI products.

Kindeva Drug Delivery, a global provider of drug-device combination products, is investing in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products. This new line will be located in its Loughborough, U.K., facility and will handle the production of pMDIs containing low-GWP (Global Warming Potential) propellants.

The new line will be capable of handling both HFA-152a and HFO-1234ze propellants. These propellants have a GWP of 90% and 99.9% lower than the industry standard HFA-134a, respectively. The line is anticipated to be operational in 2026.

This investment comes in response to an increased customer demand for more sustainable pMDI products and considers the recent adoption of F-gas legislation in the European Union. The phase-down of the existing propellants will commence in 2027 in the EU and be completed by the end of 2029.

Milton Boyer, Kindeva’s CEO, expressed his excitement about this new venture. He said, “With a track record of nearly 70 years in pMDIs — including the invention of the pMDI in 1956 and leading the CFC- to HFA-inhaler transition in the 1990s — we are excited to be a part of this industry-wide switch in the pMDI space. Kindeva is doing everything we can to ensure a greener future for all stakeholders by doubling down on our commitment to the low-GWP evolution.”